CN109824756A - Contain 4-(benzenesulfonyl) phenylalanine derivative and the preparation method and application thereof of piperazine -2- ketone - Google Patents
Contain 4-(benzenesulfonyl) phenylalanine derivative and the preparation method and application thereof of piperazine -2- ketone Download PDFInfo
- Publication number
- CN109824756A CN109824756A CN201910206946.6A CN201910206946A CN109824756A CN 109824756 A CN109824756 A CN 109824756A CN 201910206946 A CN201910206946 A CN 201910206946A CN 109824756 A CN109824756 A CN 109824756A
- Authority
- CN
- China
- Prior art keywords
- dichloromethane
- reaction
- room temperature
- solution
- sulfonyl chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 title 2
- GACRMEJERCJJAQ-AWEZNQCLSA-N (2S)-2-amino-3-[4-(benzenesulfonyl)phenyl]propanoic acid Chemical class C1=CC(C[C@H](N)C(O)=O)=CC=C1S(=O)(=O)C1=CC=CC=C1 GACRMEJERCJJAQ-AWEZNQCLSA-N 0.000 title 1
- 150000002993 phenylalanine derivatives Chemical class 0.000 claims abstract description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 165
- 150000001875 compounds Chemical class 0.000 claims description 57
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 51
- 238000006243 chemical reaction Methods 0.000 claims description 42
- -1 nitro, amino Chemical group 0.000 claims description 30
- 239000012074 organic phase Substances 0.000 claims description 29
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 28
- 239000002904 solvent Substances 0.000 claims description 24
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical class ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 claims description 23
- 230000002829 reductive effect Effects 0.000 claims description 23
- 238000001704 evaporation Methods 0.000 claims description 21
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 20
- 238000003756 stirring Methods 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- JPYWLNSEDGYUKM-UHFFFAOYSA-N 4-(benzenesulfonyl)piperazin-2-one Chemical compound C1CNC(=O)CN1S(=O)(=O)C1=CC=CC=C1 JPYWLNSEDGYUKM-UHFFFAOYSA-N 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 239000012043 crude product Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 238000012544 monitoring process Methods 0.000 claims description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 10
- 238000010898 silica gel chromatography Methods 0.000 claims description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 claims description 7
- JFXDIXYFXDOZIT-UHFFFAOYSA-N 4-methoxy-n-methylaniline Chemical compound CNC1=CC=C(OC)C=C1 JFXDIXYFXDOZIT-UHFFFAOYSA-N 0.000 claims description 7
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 7
- 239000000741 silica gel Substances 0.000 claims description 7
- 229910002027 silica gel Inorganic materials 0.000 claims description 7
- FCMLWBBLOASUSO-UHFFFAOYSA-N tert-butyl 3-oxopiperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNC(=O)C1 FCMLWBBLOASUSO-UHFFFAOYSA-N 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 4
- 238000006482 condensation reaction Methods 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- ZSZKAQCISWFDCQ-UHFFFAOYSA-N 2-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=CC=C1S(Cl)(=O)=O ZSZKAQCISWFDCQ-UHFFFAOYSA-N 0.000 claims description 3
- WPHUUIODWRNJLO-UHFFFAOYSA-N 2-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC=C1S(Cl)(=O)=O WPHUUIODWRNJLO-UHFFFAOYSA-N 0.000 claims description 3
- OKYSUJVCDXZGKE-UHFFFAOYSA-N 3-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=CC(S(Cl)(=O)=O)=C1 OKYSUJVCDXZGKE-UHFFFAOYSA-N 0.000 claims description 3
- MWWNNNAOGWPTQY-UHFFFAOYSA-N 3-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=CC(S(Cl)(=O)=O)=C1 MWWNNNAOGWPTQY-UHFFFAOYSA-N 0.000 claims description 3
- KMMHZIBWCXYAAH-UHFFFAOYSA-N 4-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)C=C1 KMMHZIBWCXYAAH-UHFFFAOYSA-N 0.000 claims description 3
- ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 4-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1 ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 0.000 claims description 3
- BFXHJFKKRGVUMU-UHFFFAOYSA-N 4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C=C1 BFXHJFKKRGVUMU-UHFFFAOYSA-N 0.000 claims description 3
- DTJVECUKADWGMO-UHFFFAOYSA-N 4-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(S(Cl)(=O)=O)C=C1 DTJVECUKADWGMO-UHFFFAOYSA-N 0.000 claims description 3
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 claims description 3
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 229940002612 prodrug Drugs 0.000 claims description 3
- 239000000651 prodrug Substances 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 2
- 150000001555 benzenes Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000007810 chemical reaction solvent Substances 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 230000006837 decompression Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- XMVJITFPVVRMHC-UHFFFAOYSA-N roxarsone Chemical group OC1=CC=C([As](O)(O)=O)C=C1[N+]([O-])=O XMVJITFPVVRMHC-UHFFFAOYSA-N 0.000 claims description 2
- 238000005694 sulfonylation reaction Methods 0.000 claims description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 230000036436 anti-hiv Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 22
- 239000003112 inhibitor Substances 0.000 abstract description 8
- NANQJUFFKXWVJR-UHFFFAOYSA-N 1-(benzenesulfonyl)piperazine Chemical compound C=1C=CC=CC=1S(=O)(=O)N1CCNCC1 NANQJUFFKXWVJR-UHFFFAOYSA-N 0.000 abstract 1
- 229940124321 AIDS medicine Drugs 0.000 abstract 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 94
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 64
- 208000031886 HIV Infections Diseases 0.000 description 22
- 230000000694 effects Effects 0.000 description 20
- 230000003595 spectral effect Effects 0.000 description 19
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 16
- 239000007787 solid Substances 0.000 description 14
- 108090000565 Capsid Proteins Proteins 0.000 description 11
- 102100023321 Ceruloplasmin Human genes 0.000 description 11
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 11
- 238000002844 melting Methods 0.000 description 9
- 230000008018 melting Effects 0.000 description 9
- DATMGURIEMIJFZ-KRWDZBQOSA-N (2S)-2-benzyl-4-bromo-N-(4-methoxyphenyl)-N-methyl-3-oxobutanamide Chemical compound CN(C1=CC=C(C=C1)OC)C(=O)[C@@H](CC2=CC=CC=C2)C(=O)CBr DATMGURIEMIJFZ-KRWDZBQOSA-N 0.000 description 7
- QXIJJKHPLSIDNS-FQEVSTJZSA-N (2S)-N-(4-methoxyphenyl)-N-methyl-2-[[2-(2-oxopiperazin-1-yl)acetyl]amino]-3-phenylpropanamide Chemical compound COC1=CC=C(C=C1)N(C([C@H](CC1=CC=CC=C1)NC(CN1C(CNCC1)=O)=O)=O)C QXIJJKHPLSIDNS-FQEVSTJZSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- RHZIAXWOSSTBDM-INIZCTEOSA-N (2s)-2-amino-n-(4-methoxyphenyl)-n-methyl-3-phenylpropanamide Chemical compound C1=CC(OC)=CC=C1N(C)C(=O)[C@@H](N)CC1=CC=CC=C1 RHZIAXWOSSTBDM-INIZCTEOSA-N 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
- 239000012268 protein inhibitor Substances 0.000 description 5
- 229940121649 protein inhibitor Drugs 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- MCIVTLFYZGLGEI-VWLOTQADSA-N (2S)-2-[[2-[4-(2-fluorophenyl)sulfonyl-2-oxopiperazin-1-yl]acetyl]amino]-N-(4-methoxyphenyl)-N-methyl-3-phenylpropanamide Chemical compound FC1=C(C=CC=C1)S(=O)(=O)N1CC(N(CC1)CC(=O)N[C@H](C(=O)N(C)C1=CC=C(C=C1)OC)CC1=CC=CC=C1)=O MCIVTLFYZGLGEI-VWLOTQADSA-N 0.000 description 2
- MAJDZGMNNWCROE-SANMLTNESA-N (2S)-2-[[2-[4-(3-fluorophenyl)sulfonyl-2-oxopiperazin-1-yl]acetyl]amino]-N-(4-methoxyphenyl)-N-methyl-3-phenylpropanamide Chemical compound FC=1C=C(C=CC=1)S(=O)(=O)N1CC(N(CC1)CC(=O)N[C@H](C(=O)N(C)C1=CC=C(C=C1)OC)CC1=CC=CC=C1)=O MAJDZGMNNWCROE-SANMLTNESA-N 0.000 description 2
- VNCJANIOCDBENF-SANMLTNESA-N (2S)-2-[[2-[4-(4-bromophenyl)sulfonyl-2-oxopiperazin-1-yl]acetyl]amino]-N-(4-methoxyphenyl)-N-methyl-3-phenylpropanamide Chemical compound BrC1=CC=C(C=C1)S(=O)(=O)N1CC(N(CC1)CC(=O)N[C@H](C(=O)N(C)C1=CC=C(C=C1)OC)CC1=CC=CC=C1)=O VNCJANIOCDBENF-SANMLTNESA-N 0.000 description 2
- SCRFLCKZIFPOPE-SANMLTNESA-N (2S)-2-[[2-[4-(4-chlorophenyl)sulfonyl-2-oxopiperazin-1-yl]acetyl]amino]-N-(4-methoxyphenyl)-N-methyl-3-phenylpropanamide Chemical compound ClC1=CC=C(C=C1)S(=O)(=O)N1CC(N(CC1)CC(=O)N[C@H](C(=O)N(C)C1=CC=C(C=C1)OC)CC1=CC=CC=C1)=O SCRFLCKZIFPOPE-SANMLTNESA-N 0.000 description 2
- UYLRPYWNGDCKIG-SANMLTNESA-N (2S)-2-[[2-[4-(4-fluorophenyl)sulfonyl-2-oxopiperazin-1-yl]acetyl]amino]-N-(4-methoxyphenyl)-N-methyl-3-phenylpropanamide Chemical compound FC1=CC=C(C=C1)S(=O)(=O)N1CC(N(CC1)CC(=O)N[C@H](C(=O)N(C)C1=CC=C(C=C1)OC)CC1=CC=CC=C1)=O UYLRPYWNGDCKIG-SANMLTNESA-N 0.000 description 2
- PLEWBCVXNOFSHO-SANMLTNESA-N (2S)-2-[[2-[4-(benzenesulfonyl)-2-oxopiperazin-1-yl]acetyl]amino]-N-(4-methoxyphenyl)-N-methyl-3-phenylpropanamide Chemical compound COC1=CC=C(C=C1)N(C([C@H](CC1=CC=CC=C1)NC(CN1C(CN(CC1)S(=O)(=O)C1=CC=CC=C1)=O)=O)=O)C PLEWBCVXNOFSHO-SANMLTNESA-N 0.000 description 2
- CUVSYFOVWHWKQG-SANMLTNESA-N (2S)-N-(4-methoxyphenyl)-N-methyl-2-[[2-[4-(3-nitrophenyl)sulfonyl-2-oxopiperazin-1-yl]acetyl]amino]-3-phenylpropanamide Chemical compound COC1=CC=C(C=C1)N(C([C@H](CC1=CC=CC=C1)NC(CN1C(CN(CC1)S(=O)(=O)C1=CC(=CC=C1)[N+](=O)[O-])=O)=O)=O)C CUVSYFOVWHWKQG-SANMLTNESA-N 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- WJYUVMGNUZXTIS-VWLOTQADSA-N (2S)-2-[[2-[4-(2-aminophenyl)sulfonyl-2-oxopiperazin-1-yl]acetyl]amino]-N-(4-methoxyphenyl)-N-methyl-3-phenylpropanamide Chemical compound NC1=C(C=CC=C1)S(=O)(=O)N1CC(N(CC1)CC(=O)N[C@H](C(=O)N(C)C1=CC=C(C=C1)OC)CC1=CC=CC=C1)=O WJYUVMGNUZXTIS-VWLOTQADSA-N 0.000 description 1
- YKKMVHPHIJVSSV-SANMLTNESA-N (2S)-2-[[2-[4-(3-aminophenyl)sulfonyl-2-oxopiperazin-1-yl]acetyl]amino]-N-(4-methoxyphenyl)-N-methyl-3-phenylpropanamide Chemical compound NC=1C=C(C=CC=1)S(=O)(=O)N1CC(N(CC1)CC(=O)N[C@H](C(=O)N(C)C1=CC=C(C=C1)OC)CC1=CC=CC=C1)=O YKKMVHPHIJVSSV-SANMLTNESA-N 0.000 description 1
- REXBCEZWZOLFMN-SANMLTNESA-N (2S)-2-[[2-[4-(4-aminophenyl)sulfonyl-2-oxopiperazin-1-yl]acetyl]amino]-N-(4-methoxyphenyl)-N-methyl-3-phenylpropanamide Chemical compound NC1=CC=C(C=C1)S(=O)(=O)N1CC(N(CC1)CC(=O)N[C@H](C(=O)N(C)C1=CC=C(C=C1)OC)CC1=CC=CC=C1)=O REXBCEZWZOLFMN-SANMLTNESA-N 0.000 description 1
- LJNTXEWLMMKPEA-MHZLTWQESA-N (2S)-N-(4-methoxyphenyl)-2-[[2-[4-(4-methoxyphenyl)sulfonyl-2-oxopiperazin-1-yl]acetyl]amino]-N-methyl-3-phenylpropanamide Chemical compound COC1=CC=C(C=C1)N(C([C@H](CC1=CC=CC=C1)NC(CN1C(CN(CC1)S(=O)(=O)C1=CC=C(C=C1)OC)=O)=O)=O)C LJNTXEWLMMKPEA-MHZLTWQESA-N 0.000 description 1
- PCNBEFBHKJNNIF-DEOSSOPVSA-N (2S)-N-(4-methoxyphenyl)-N-methyl-2-[[2-[4-(2-nitrophenyl)sulfonyl-2-oxopiperazin-1-yl]acetyl]amino]-3-phenylpropanamide Chemical compound COC1=CC=C(C=C1)N(C([C@H](CC1=CC=CC=C1)NC(CN1C(CN(CC1)S(=O)(=O)C1=C(C=CC=C1)[N+](=O)[O-])=O)=O)=O)C PCNBEFBHKJNNIF-DEOSSOPVSA-N 0.000 description 1
- HFCNJHUYLSBJBB-SANMLTNESA-N (2S)-N-(4-methoxyphenyl)-N-methyl-2-[[2-[4-(4-nitrophenyl)sulfonyl-2-oxopiperazin-1-yl]acetyl]amino]-3-phenylpropanamide Chemical compound COC1=CC=C(C=C1)N(C([C@H](CC1=CC=CC=C1)NC(CN1C(CN(CC1)S(=O)(=O)C1=CC=C(C=C1)[N+](=O)[O-])=O)=O)=O)C HFCNJHUYLSBJBB-SANMLTNESA-N 0.000 description 1
- 101710164563 Beta-catenin-like protein 1 Proteins 0.000 description 1
- 102100031109 Beta-catenin-like protein 1 Human genes 0.000 description 1
- NMCUXOXCCKVSFK-INIZCTEOSA-N CN(C([C@H](CC1=CC=CC=C1)OC(N)=O)=O)C(C=C1)=CC=C1OC Chemical compound CN(C([C@H](CC1=CC=CC=C1)OC(N)=O)=O)C(C=C1)=CC=C1OC NMCUXOXCCKVSFK-INIZCTEOSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 229940124765 capsid inhibitor Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940124524 integrase inhibitor Drugs 0.000 description 1
- 239000002850 integrase inhibitor Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108700004028 nef Genes Proteins 0.000 description 1
- 101150023385 nef gene Proteins 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000048 toxicity data Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of phenylalanine derivatives and its preparation method and application for containing 4- (benzenesulfonyl) piperazine -2- ketone.The derivative has structure shown in following general formula I.The application in anti-AIDS drug is being prepared the invention further relates to the preparation method of the analog derivative and its as HIV-1 inhibitor.
Description
Technical Field
The invention belongs to the technical field of organic compound synthesis and medical application, and particularly relates to a phenylalanine derivative containing 4- (benzenesulfonyl) piperazine-2-ketone, and a preparation method and application thereof.
Background
Acquired Immune Deficiency Syndrome (AIDS) is a serious infectious disease that endangers Human life and health, mainly caused by Human Immunodeficiency Virus Type I (HIV-1). Currently, clinically applied drugs for treating aids mainly include: reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors and invasion inhibitors. The high-efficiency Antiretroviral Therapy (HAART) prolongs the survival time of patients to a great extent and improves the life quality of the patients, but the problems of drug resistance, drug toxic and side effects, latent infection, high cost of long-term taking of drugs and the like greatly reduce the efficacy of the Therapy, limit the application of the Therapy and further force researchers to develop anti-AIDS drugs with new targets, new mechanisms and new structures.
The HIV-1 capsid is assembled from a portion of the Gag precursor protein that is cleaved to yield capsid protein units. During the conversion of immature virions to mature virions, capsid proteins assemble into capsids, encapsulating viral RNA and nuclear-associated proteins (reverse transcriptase, protease, integrase, etc.) to form mature HIV-1 virions. The mature virus particle is infectious and the next round of replication of the virus can take place. In recent years, with the researchers' deep knowledge of capsid protein structure, the related information of crystal structure is reported in succession. Therefore, the capsid protein of HIV-1 can be used as the action target of a novel anti-HIV-1 medicament.
The Pfizer company obtains a compound PF-74 capable of obviously inhibiting HIV-1 replication through high-throughput screening of a compound library, and the structure-activity relationship and mechanism research of the compound shows that the compound interferes with the uncoating process of viruses and the process of forming infectious particles by combining HIV-1 capsid protein. Although PF-74 has novel structure, unique mechanism and definite target, PF-74 has lower curative effect, poorer drug-like property and is easy to induce drug resistance compared with the anti-HIV-1 drug on the market at present. Therefore, the development of capsid protein inhibitors with higher efficacy and good drug-like and drug-resistance is an attractive direction in the development field of anti-aids drugs in recent years.
According to the crystal structure characteristics of the binding site of the PF-74 and HIV-1 capsid protein, the phenylalanine HIV-1 capsid protein inhibitor of 4- (phenylsulfonyl) piperazine-2-ketone with a brand-new structure is discovered through reasonable drug design, chemical synthesis and biological activity evaluation, and the problems of low curative effect, poor drug property and drug resistance of the existing HIV-1 capsid protein inhibitor are hopefully improved.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a phenylalanine derivative containing 4- (benzenesulfonyl) piperazine-2-ketone and a preparation method thereof, and also provides an activity screening result of the compound as an HIV-1 capsid protein inhibitor and an application thereof.
The technical scheme of the invention is as follows:
1. phenylalanine derivatives containing 4- (phenylsulfonyl) piperazin-2-one
A phenylalanine derivative containing 4- (phenylsulfonyl) piperazin-2-one, or a pharmaceutically acceptable salt, ester, or prodrug thereof, having the structure shown in formula I:
wherein,
r is: c1-C6Alkyl, OC1-C6Alkyl radical, C2-C6Alkenyl radical, C3-C6Cycloalkyl, OC3-C6Cycloalkyl, substituted benzene ring, substituted benzyl, substituted naphthalene ring, various substituted six-membered heterocyclic rings or various substituted five-membered heterocyclic rings, H, OH, halogen, nitro, amino, cyano, trifluoromethyl or trifluoromethoxy.
In accordance with a preferred aspect of the present invention,
r is: H. 4-F, 3-F, 2-F, 4-Cl, 3-Cl, 2-Cl, 4-Br, 3-Br, 2-Br, 4-methoxy, 3-methoxy, 2-methoxy, 4-methyl, 3-methyl, 2-methyl, 4-nitro, 3-nitro, 2-nitro, 4-amino, 3-amino and 2-amino.
According to a further preferred embodiment of the invention, the phenylalanine derivative containing 4- (phenylsulfonyl) piperazin-2-one is one of the following compounds:
as used herein, "pharmaceutically acceptable salts" means salts of the compounds which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and lower animals without undue toxicity, irritation, and allergic response and the like, are commensurate with a reasonable benefit-to-risk ratio, are generally water or oil soluble or dispersible, and are effective for their intended use. Including pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts, which are contemplated herein and are compatible with the chemical nature of the compounds of formula I. A list of suitable salts is found on pages 1-19 of s.m. berge et al, j.pharm.sci.,1977, 66.
The term "prodrug" as used herein refers to pharmaceutically acceptable derivatives such that the resulting biotransformation product of these derivatives is the active drug as defined for the compound of formula I.
2. Preparation method of phenylalanine derivative containing 4- (benzenesulfonyl) piperazine-2-ketone
A method for preparing a phenylalanine derivative containing 4- (phenylsulfonyl) piperazin-2-one comprising the steps of: generating an intermediate 2 with Boc-L-phenylalanine 1 as an initial raw material and dichloromethane as a reaction solvent through an amide condensation reaction and N-methyl-4-aminoanisole; then the intermediate 2 is dissolved in a proper amount of dichloromethane, and Boc groups are removed under the action of trifluoroacetic acid to obtain an intermediate 3; then, carrying out amide condensation reaction on the intermediate 3 and bromoacetic acid to obtain an intermediate 4; the intermediate 4 and 3-oxo-1-piperazine carboxylic acid tert-butyl ester take nucleophilic substitution reaction by taking dichloromethane as a solvent to obtain an intermediate 5; then, dissolving the intermediate 5 in a proper amount of dichloromethane solution, and removing Boc groups under the action of trifluoroacetic acid to obtain an intermediate 6; finally, the intermediate 6 and the corresponding substituted benzene sulfonyl chloride are subjected to sulfonylation reaction to obtain a target compound (7 a-k); the compound (7i-k) is further reduced by hydrogenation to give the objective compound (7 l-n).
The synthetic route is as follows:
reagents and conditions: (i) n-methyl-4-aminoanisole, 1H-benzotriazole-1-yloxytripyrrolidinyl hexafluorophosphate, N, N-diisopropylethylamine and dichloromethane are added, and the temperature is changed to room temperature at 0 ℃; (ii) trifluoroacetic acid, dichloromethane, room temperature; (iii) bromoacetic acid, O- (7-azabenzotriazol-1-yl) -N, N, N ', N' -tetramethyluronium hexafluorophosphate, N, N-diisopropylethylamine and dichloromethane, and the temperature is changed to room temperature at 0 ℃; (iv) 3-oxo-1-piperazine carboxylic acid tert-butyl ester, potassium carbonate and N, N-dimethylformamide, and the temperature is changed to 40 ℃ at room temperature; (v) trifluoroacetic acid, dichloromethane, room temperature; (vi) correspondingly substituted benzene sulfonyl chloride, triethylamine and dichloromethane are cooled to room temperature at 0 ℃; (vii) h210% Pd. C, dichloromethane/methanol, room temperature.
Wherein R is as described in formula I above.
The substituted benzene sulfonyl chloride is benzene sulfonyl chloride, 4-fluorobenzene sulfonyl chloride, 3-fluorobenzene sulfonyl chloride, 2-fluorobenzene sulfonyl chloride, 4-chlorobenzene sulfonyl chloride, 4-bromobenzene sulfonyl chloride, 4-methoxybenzene sulfonyl chloride, 4-methylbenzene sulfonyl chloride, 4-nitrobenzene sulfonyl chloride, 3-nitrobenzene sulfonyl chloride and 2-nitrobenzene sulfonyl chloride.
The room temperature of the invention is 20-30 ℃.
The preferred preparation method of the phenylalanine derivative containing 4- (benzenesulfonyl) piperazine-2-ketone comprises the following steps:
(1) adding Boc-L-phenylalanine 1 and 1H-benzotriazole-1-yloxytripyrrolidinyl hexafluorophosphate into dichloromethane, and stirring for 30min under an ice bath condition; adding N, N-diisopropylethylamine and N-methyl-4-aminoanisole into the reaction solution, removing the ice bath, transferring to room temperature, and monitoring by TLC; after the reaction is finished, evaporating the solvent under reduced pressure, then adding a saturated sodium bicarbonate solution into the residue in the bottle, extracting with dichloromethane, separating an organic phase, adding a 1N HCl solution for washing, separating the organic phase, adding a saturated sodium chloride solution for washing, drying the organic phase with anhydrous sodium sulfate, filtering, concentrating the filtrate under reduced pressure, and separating and purifying the obtained crude product by silica gel column chromatography to obtain an intermediate 2;
(2) adding the intermediate 2 obtained in the previous step into dichloromethane, slowly dropwise adding excessive trifluoroacetic acid into the solution under the condition of ice bath and stirring, then removing the ice bath, transferring to room temperature, and monitoring by TLC; after the reaction is finished, evaporating the solvent under reduced pressure, adding a saturated sodium bicarbonate solution to adjust the pH of the reaction solution to 7, and then adding a dichloromethane solution for extraction; separating and taking an organic phase, washing the organic phase for 3 times by using a saturated sodium chloride solution, drying the organic phase by using anhydrous sodium sulfate, filtering, and evaporating the solvent to dryness under reduced pressure to obtain an intermediate 3;
(3) adding bromoacetic acid and O- (7-azabenzotriazole-1-yl) -N, N, N ', N' -tetramethylurea hexafluorophosphate into dichloromethane, and stirring for 1h under an ice bath condition; then adding the intermediate 3 and N, N-diisopropylethylamine into the solution, removing the ice bath, and stirring at room temperature for 6 h; after the reaction is finished, filtering, decompressing and evaporating the solvent, and separating by silica gel column chromatography to obtain an intermediate 4;
(4) adding the intermediate 4, the tert-butyl 3-oxo-1-piperazinecarboxylate and potassium carbonate into N, N-dimethylformamide, and stirring for 12 hours from room temperature to 40 ℃; after the reaction is finished, adding a proper amount of saturated sodium chloride solution into the reaction solution, extracting with ethyl acetate, drying an organic phase with anhydrous sodium sulfate, filtering, evaporating the solvent under reduced pressure, and separating by silica gel column chromatography to obtain an intermediate 5;
(5) adding the intermediate 5 into dichloromethane, slowly adding trifluoroacetic acid into the dichloromethane under the condition of ice bath and stirring, then removing the ice bath, transferring the mixture to room temperature, and monitoring by TLC; after the reaction is finished, evaporating the solvent under reduced pressure, adding a saturated sodium bicarbonate solution to adjust the pH of the reaction solution to 7, and then adding a dichloromethane solution for extraction; separating and taking an organic phase, washing the organic phase for 3 times by using a saturated sodium chloride solution, drying the organic phase by using anhydrous sodium sulfate, filtering, and evaporating the solvent to dryness under reduced pressure to obtain an intermediate 6;
(6) adding the intermediate 6 and triethylamine into dichloromethane, slowly adding the corresponding substituted benzenesulfonyl chloride into the dichloromethane under the condition of ice bath and stirring, removing the ice bath, transferring to room temperature, and monitoring by TLC; after the reaction is finished, adding saturated sodium chloride solution, extracting by dichloromethane, separating and taking an organic phase, drying by using anhydrous sodium sulfate, filtering, evaporating the solvent by decompression, separating by silica gel column chromatography to obtain a crude product of the target compound, and recrystallizing by ethyl acetate to obtain a pure product (7a-k) of the target compound;
(7) dissolving a target compound (7i-k) in methanol and dichloromethane, adding 10% Pd & C, replacing with hydrogen for three times, and stirring at room temperature for two hours under the protection of a hydrogen balloon; after the reaction is finished, adding diatomite for filtration, evaporating the filtrate to dryness to obtain a crude product of the target compound, and purifying by a silica gel preparation plate to obtain a pure product (7l-7n) of the target compound.
3. Use of phenylalanine derivatives containing 4- (phenylsulfonyl) piperazin-2-one
The invention discloses a screening result of anti-HIV-1 activity of a phenylalanine derivative containing 4- (benzenesulfonyl) piperazine-2-ketone and an application thereof as an HIV-1 inhibitor for the first time. Experiments prove that the phenylalanine derivative containing 4- (benzenesulfonyl) piperazine-2-ketone can be used as an HIV-1 inhibitor for preparing anti-AIDS medicaments. The invention also provides application of the compound in preparing anti-HIV-1 medicines.
anti-HIV-1 Activity and toxicity test of the target Compound
A class of phenylalanine derivatives containing 4- (phenylsulfonyl) piperazin-2-one synthesized as described above were tested for anti-HIV-1 activity and toxicity at the cellular level, and their anti-HIV-1 activity and toxicity data are shown in Table 1, with the literature-reported capsid protein inhibitor PF-74 as a positive control.
The newly synthesized phenylalanine derivative containing 4- (benzenesulfonyl) piperazine-2-ketone shows remarkable anti-HIV-1 activity. For example, the anti-HIV-1 activity of the target compounds 7a, 7c, 7d, 7f, 7h, 7i, 7l, 7M, 7n was in the range of 0.09-0.54. mu.M, which was superior to that of the positive control PF-74 (EC)50＝0.52±0.18μM,CC50>47.00,SI>90.91) or equivalent, wherein the anti-HIV-1 activity (EC) of 7l of the compound of interest50＝0.09±0.03μM,CC50>34.50,SI>383.36) has great significance in further research.
The phenylalanine derivatives containing 4- (benzenesulfonyl) piperazine-2-ketone can be used as HIV-1 inhibitors. In particular to the application of the compound as an HIV-1 inhibitor in preparing anti-AIDS drugs.
An anti-HIV-1 pharmaceutical composition comprises a class of phenylalanine derivatives containing 4- (phenylsulfonyl) piperazin-2-one of the present invention and one or more pharmaceutically acceptable carriers or excipients.
The invention provides a phenylalanine derivative containing 4- (benzenesulfonyl) piperazine-2-ketone and a preparation method thereof, and also provides a screening result of anti-HIV-1 activity of partial compounds and the first application thereof in the field of antivirus. Tests prove that the phenylalanine derivatives containing 4- (benzenesulfonyl) piperazine-2-one can be used as HIV-1 inhibitors and have high application value. In particular to the application of the compound as an HIV-1 inhibitor in preparing anti-AIDS drugs.
Detailed Description
The invention will be understood by the following examples, which are given by way of illustration and are not intended to limit the scope of the invention.
Example 1: preparation of tert-butyl (S) - (1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) carbamate (2)
The starting material Boc-L-phenylalanine (1) (2.90g,10.93mmol,1.5eq.) and 1H-benzotriazole-1-yloxytripyrrolidinyl hexafluorophosphate (5.69g,10.93mmol,1.5eq) were added to 20mL of dichloromethane and stirred under ice bath conditions for 30 min; then N, N-diisopropylethylamine (3.61mL,21.87mmol,3eq.) and N-methyl-4-aminoanisole (1.0g, 7.29mmol,1eq.) were added, the ice bath was removed and the mixture was stirred at room temperature and monitored by TLC; after 6h, the reaction was completed, the solvent was evaporated under reduced pressure, then 40mL of saturated sodium bicarbonate solution and 40mL of dichloromethane were added to the residue in the flask for extraction, the organic phase was separated and washed with 40mL of 1N HCl solution, the organic phase was separated and washed with 40mL of saturated sodium chloride solution, the organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give a crude product of tert-butyl (2) intermediate (S) - (1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) carbamate (2), 2.48g of which was a yellow oily substance, in 89% yield, which was obtained by silica gel column chromatography (eluent EA: PE ═ 1: 8).
Spectral data:
1H NMR(400MHz,DMSO-d6)δ7.22(d,J＝8.3Hz,2H,Ph-H),7.20–7.11(m,3H,Ph-H),7.09(d,J＝8.2Hz,1H,NH),7.03(d,J＝8.6Hz,2H,Ph-H),6.79(d,J＝7.3Hz,2H,Ph-H),4.27–4.06(m,1H,CH),3.81(s,3H,OCH3),3.13(s,3H,NCH3),2.75(dd,J＝13.4,3.8Hz,1H,PhCH),2.61(dd,J＝13.3,10.3Hz,1H,PhCH),1.30(s,9H,C(CH3)3).
13C NMR(100MHz,DMSO-d6)δ172.22(C＝O),158.98,155.75(C＝O),138.53(2×C),136.12(2×C),129.28(2×C),128.47(2×C),126.70,115.21(2×C),78.33,55.94,53.55,37.86,37.07,28.65(3×C).
ESI-MS:m/z 385.4(M+1),407.5(M+23).C22H28N2O4[384.5].
example 2: preparation of (S) -2-amino-N- (4-methoxyphenyl) -N-methyl-3-phenylpropionamide (3)
Intermediate 2(4.0g,10.40mmol,1.0eq.) was added to 30mL of dichloromethane, and trifluoroacetic acid (3.86mL,52.02mmol,5.0eq.) was then added slowly to this solution, stirred at room temperature, monitored by TLC; after 1h, the reaction was completed, and then the reaction solution was adjusted to pH 7 with saturated sodium bicarbonate solution, extracted with 40mL of dichloromethane, the organic phase was separated, washed with saturated sodium chloride solution (20 mL. times.3 times), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain 2.36g of a crude product of intermediate (S) -2-amino-N- (4-methoxyphenyl) -N-methyl-3-phenylacrylamide (3), as a yellow oil, in 80% yield.
Spectral data:
1H NMR(400MHz,DMSO-d6)δ7.29–7.13(m,3H,Ph-H),7.03–6.75(m,6H,Ph-H),3.77(s,3H,OCH3),3.44–3.35(m,1H,CH),3.06(s,3H,NCH3),2.75(dd,J＝12.8,6.7Hz,1H,PhCH),2.45(dd,J＝12.9,7.1Hz,1H,PhCH),1.87(s,2H,NH2).
13C NMR(100MHz,DMSO-d6)δ174.89(C＝O),158.75,139.00,136.35,129.51(2×C),128.93(2×C),128.47(2×C),126.55,115.04(2×C),55.85,53.35,42.19,37.45.
ESI-MS:m/z 285.05(M+1).C17H20N2O2[284.36].
example 3: preparation of intermediate (S) -2- (2-bromoacetyl) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (4)
Bromoacetic acid (117mg,0.84mmol,1.2eq.), O- (7-azabenzotriazol-1-yl) -N, N' -tetramethyluronium hexafluorophosphate (401mg,1.06mmol,1.5eq.) were added to 15mL dichloromethane and stirred under ice bath conditions for 1 h; to this solution was then added intermediate 3(200mg,0.70mmol,1eq.) and N, N-diisopropylethylamine (232 μ L,1.41mmol,2eq.), removed from the ice bath, stirred at room temperature, monitored by TLC; after completion of the reaction for 6 hours, the solvent was distilled off under reduced pressure, and the residue was separated by column chromatography on silica gel (eluent EA: PE ═ 1:4+ 2.5% triethylamine) to give 190mg of intermediate (S) -2- (2-bromoacetyl) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropionamide (4) as a white oil in 68% yield.
Spectral data:
ESI-MS:m/z 405.4(M+1).C19H21BrN2O3[404.1].
example 4: preparation of intermediate (S) -tert-butyl 4- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -3-tert-butyloxopiperazine-1-carboxylate (5)
Intermediate 4(700mg,1.73mmol,1eq.) and tert-butyl 3-oxo-1-piperazinecarboxylate (415mg,2.07mmol,1.2eq.), potassium carbonate (477mg,3.45mmol,2eq.) were added to N, N-dimethylformamide (6mL) and stirred from room temperature to 40 ℃ for 12 h; after the reaction, 20mL of a saturated sodium chloride solution was added to the reaction mixture, and the mixture was extracted with ethyl acetate (20mL × 3 times), the organic phase was dried over anhydrous sodium sulfate, filtered, the solvent was evaporated under reduced pressure, and the intermediate (S) -tert-butyl 4- (2- ((1- ((4-methoxyphenyl) (methyl) amino) -1-oxo-3-phenylpropan-2-yl) amino) -2-oxoethyl) -3-tert-butyloxopiperazine-1-carboxylate (5) was obtained by silica gel column chromatography in 360mg of a white solid, yield 40%, melting point: 138 ℃ and 139 ℃.
Spectral data:
ESI-MS:m/z 523.09(M-1).C28H36N4O6[524.62].
example 5: preparation of intermediate (S) -N- (4-methoxyphenyl) -N-methyl-2- (2- (2-oxopiperazin-1-yl) acetylamino) -3-phenylpropanamide (6)
Intermediate 5(158mg,0.301mmol) was added to dichloromethane (5mL) and trifluoroacetic acid (2mL) was added slowly thereto with stirring under ice bath conditions, followed by removal of the ice bath to room temperature and monitoring by TLC; after 4h, after the reaction is finished, the solvent is evaporated under reduced pressure, then a saturated sodium bicarbonate solution is added to adjust the pH of the reaction solution to 7, and then 20mL of dichloromethane solution is added for extraction; the organic phase was separated, washed with saturated sodium chloride solution (20mL × 3 times), dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated under reduced pressure to obtain 80mg of intermediate (S) -N- (4-methoxyphenyl) -N-methyl-2- (2- (2-oxopiperazin-1-yl) acetylamino) -3-phenylpropionamide (6) as a yellow oil with a yield of 63%.
Spectral data:
ESI-MS:m/z 425.4(M+1),447.4(M+23).C23H28N4O4[424.5].
example 6: preparation of target Compound (7a-k)
Dissolving the intermediate 6(1eq.) and triethylamine (2eq.) in 10mL of dichloromethane, slowly adding the corresponding substituted benzenesulfonyl chloride (1.5eq.) while stirring in an ice bath, removing the ice bath, transferring to room temperature, and monitoring by TLC; after the reaction is finished, 20mL of saturated sodium chloride solution is added, then dichloromethane is added for extraction (20mL multiplied by 3 times), an organic phase is separated, dried by anhydrous sodium sulfate, filtered, and the solvent is evaporated to dryness under reduced pressure to obtain a crude product of the target compound, and the crude product of the target compound is purified by a silica gel preparation plate or recrystallized by ethyl acetate to obtain a pure product (7a-k) of the target compound.
Reaction of the correspondingly substituted benzenesulfonyl chloride with benzenesulfonyl chloride (45 μ L,0.35mmol,1.5eq.) with intermediate 6(100mg,0.24mmol, 1eq.), triethylamine (65 μ L,0.47mmol,2eq.) gave 65mg of (S) -N- (4-methoxyphenyl) -N-methyl-2- (2- (2-oxo-4- (phenylsulfonyl) piperazin-1-yl) acetylamino) -3-phenylpropanamide (7a) as a white powdery solid in 49% yield, melting point: 84-85 ℃.
Spectral data:
1H NMR(400MHz,DMSO-d6)δ8.38(d,J＝7.9Hz,1H,NH),7.87–7.73(m,3H,Ph-H),7.68(t,J＝7.5Hz,2H,Ph-H),7.22–7.14(m,3H,Ph-H),7.11(d,J＝8.1Hz,2H,Ph-H),6.97(d,J＝8.8Hz,2H,Ph-H),6.87–6.77(m,2H,Ph-H),4.43(td,J＝8.8,5.1Hz,1H,CH),3.88–3.80(m,2H,piperazine-CH2),3.78(s,3H,OCH3),3.55(d,J＝16.2Hz,1H,piperazineCH),3.49(d,J＝16.2Hz,1H,piperazineCH),3.25–3.11(m,4H,piperazine-CH2×2),3.09(s,3H,NCH3),2.83(dd,J＝13.5,4.8Hz,1H,PhCH),2.62(dd,J＝13.4,9.5Hz,1H,PhCH).
13C NMR(100MHz,DMSO-d6)δ171.36(C＝O),167.32(C＝O),163.62(C＝O),159.00,137.90,135.99,134.83,134.18,130.12(2×C),129.28(2×C),129.12(2×C),128.59(2×C),128.12(2×C),126.88,115.13(2×C),55.89,51.82,48.99,48.41,46.95,43.20,37.77,37.68.
ESI-HRMS:m/z 565.2112(M+1),1151.3958(2M+23).C29H32N4O6S[564.2043].
reaction of the correspondingly substituted benzenesulfonyl chloride with 4-fluorobenzenesulfonyl chloride (103mg,0.53mmol,1.5eq.) with intermediate 6(150mg,0.35mmol, 1eq.), triethylamine (98 μ L,0.71mmol,2eq.) gave 73mg of (S) -2- (2- (4- ((4-fluorophenyl) sulfonyl) -2-oxopiperazin-1-yl) acetamido) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (7b) as a white solid in 35% yield, m.p.: 199 ℃ and 200 ℃.
Spectral data:
1H NMR(400MHz,DMSO-d6)δ8.38(d,J＝7.9Hz,1H,NH),7.90(dd,J＝8.6,5.2Hz,2H,Ph-H),7.52(t,J＝8.7Hz,2H,Ph-H),7.24–7.14(m,3H,Ph-H),7.11(d,J＝8.0Hz,2H,Ph-H),6.97(d,J＝8.7Hz,2H,Ph-H),6.90–6.75(m,2H,Ph-H),4.43(td,J＝8.7,5.1Hz,1H,CH),3.88(d,J＝16.5Hz,1H,piperazine-CH),3.85(d,J＝16.4Hz,1H,piperazine-CH),3.79(s,3H,OCH3),3.58(d,J＝16.3Hz,1H,piperazine-CH),3.52(d,J＝16.2Hz,1H,piperazine-CH),3.28–3.18(m,2H,piperazine-CH2),3.16(m,2H,piperazine-CH2),3.10(s,3H,NCH3),2.84(dd,J＝13.4,4.7Hz,1H,PhCH),2.62(dd,J＝13.4,9.5Hz,1H,PhCH).
13C NMR(100MHz,DMSO-d6)δ171.37(C＝O),167.32(C＝O),165.41(d,1JCF＝250.9Hz),163.62(C＝O),159.00,137.90,135.89,131.35(2×C),131.25,129.28(2×C),129.12(2×C),128.59(2×C),126.88,117.45,117.22,115.12(2×C),55.88,51.82,48.93,48.40,46.91,43.13,37.76,37.69.
ESI-HRMS:m/z 583.2020(M+1),1187.3740(2M+23).C29H31FN4O6S[582.1948].
reaction of the correspondingly substituted benzenesulfonyl chloride with 3-fluorobenzenesulfonyl chloride (75 μ L,0.57mmol,1.5eq.) with intermediate 6(160mg,0.38mmol, 1eq.), triethylamine (104 μ L,0.75mmol,2eq.) gave 90mg of (S) -2- (2- (4- ((3-fluorophenyl) sulfonyl) -2-oxopiperazin-1-yl) acetamido) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (7c) as a white solid in 41% yield, m.p.: 182 ℃ and 183 ℃.
Spectral data:
1H NMR(400MHz,DMSO-d6)δ8.38(d,J＝7.9Hz,1H,NH),7.81–7.57(m,4H,Ph-H),7.24–7.14(m,3H,Ph-H),7.11(d,J＝7.9Hz,2H,Ph-H),6.97(d,J＝8.7Hz,2H,Ph-H),6.82(d,J＝6.6Hz,2H,Ph-H),4.43(td,J＝8.7,5.3Hz,1H,CH),3.88(d,J＝16.6Hz,1H,piperazine-CH),3.83(d,J＝16.8Hz,1H,piperazine-CH),3.79(s,3H,OCH3),3.62(d,J＝16.2Hz,1H,piperazine-CH),3.56(d,J＝16.3Hz,1H,piperazine-CH),3.29–3.21(m,2H,piperazine-CH2),3.20–3.12(m,2H,piperazine-CH2),3.10(s,3H,NCH3),2.84(dd,J＝13.5,4.7Hz,1H,PhCH),2.62(dd,J＝13.4,9.5Hz,1H,PhCH).
13C NMR(100MHz,DMSO-d6)δ171.37(C＝O),167.33(C＝O),163.60(C＝O),162.47(d,1JCF＝247.6Hz),159.00,137.90,137.12(d,3JCF＝6.8Hz),135.90,132.48(d,3JCF＝7.9Hz),129.28(2×C),129.13(2×C),128.59(2×C),126.88,124.41(d,4JCF＝3.0Hz),121.35(d,2JCF＝21.0Hz),115.34,115.13(2×C),55.88,51.83,48.89,48.42,46.95,43.17,37.76,37.68.
ESI-HRMS:m/z 583.2017(M+1),1187.3844(M+23).C29H31FN4O6S[582.1948].
reaction of the corresponding substituted benzenesulfonyl chloride with 2-fluorobenzenesulfonyl chloride (103mg,0.53mmol,1.5eq.) with intermediate 6(150mg,0.35mmol, 1eq.), triethylamine (98 μ L,0.71mmol,2eq.) gave 91mg of (S) -2- (2- (4- ((2-fluorophenyl) sulfonyl) -2-oxopiperazin-1-yl) acetamido) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (7d) as a white solid in 44% yield, m.p.: 170 ℃ and 171 ℃.
Spectral data:
1H NMR(400MHz,DMSO-d6)δ8.39(d,J＝7.9Hz,1H,NH),7.91–7.75(m,2H,Ph-H),7.60–7.50(m,1H,Ph-H),7.47(t,J＝7.6Hz,1H,Ph-H),7.23–7.15(m,3H,Ph-H),7.12(d,J＝7.8Hz,2H,Ph-H),6.98(d,J＝8.7Hz,2H,Ph-H),6.88–6.80(m,2H,Ph-H),4.45(td,J＝8.7,5.2Hz,1H,CH),3.91(d,J＝16.5Hz,1H,piperazine-CH),3.86(d,J＝16.6Hz,1H,piperazine-CH),3.80(s,3H,OCH3),3.73(d,J＝16.3Hz,1H,piperazine-CH),3.70(d,J＝16.2Hz,1H,piperazine-CH),3.38(t,J＝4.9Hz,2H,piperazine-CH2),3.24–3.13(m,2H,piperazine-CH2),3.11(s,3H,NCH3),2.85(dd,J＝13.5,4.8Hz,1H,PhCH),2.63(dd,J＝13.4,9.5Hz,1H,PhCH).
13C NMR(100MHz,DMSO-d6)δ171.37(C＝O),167.34(C＝O),163.69(C＝O),159.00,158.82(d,1JCF＝252.5Hz),137.91,136.92(d,3JCF＝8.7Hz),135.91,131.44,129.28(2×C),129.13(2×C),128.59(2×C),126.88,125.81(d,4JCF＝3.5Hz),124.15(d,2JCF＝14.5Hz),118.24(d,2JCF＝21.5Hz),115.14(2×C),55.89,51.83,48.47,48.43,47.11,42.79,37.77,37.70.
ESI-HRMS:m/z 583.2017(M+1),1187.3790(2M+23).C29H31FN4O6S[582.1948].
reaction of the correspondingly substituted benzenesulfonyl chloride with 4-chlorobenzenesulfonyl chloride (112mg,0.53mmol,1.5eq.) with intermediate 6(150mg,0.35mmol, 1eq.), triethylamine (98 μ L,0.71mmol,2eq.) gave 93mg of (S) -2- (2- (4- ((4-chlorophenyl) sulfonyl) -2-oxopiperazin-1-yl) acetamido) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropionamide (7e) as a white solid in 44% yield, melting point: 203 ℃ and 204 ℃.
Spectral data:
1H NMR(400MHz,DMSO-d6)δ8.38(d,J＝8.0Hz,1H,NH),7.83(d,J＝8.6Hz,2H,Ph-H),7.74(d,J＝8.6Hz,2H,Ph-H),7.25–7.14(m,3H,Ph-H),7.11(d,J＝8.0Hz,2H,Ph-H),6.97(d,J＝8.8Hz,2H,Ph-H),6.88–6.74(m,2H,Ph-H),4.44(td,J＝8.7,5.2Hz,1H,CH),3.88(d,J＝16.5Hz,1H,piperazine-CH),3.83(d,J＝16.6Hz,1H,piperazine-CH),3.79(s,3H,OCH3),3.59(d,J＝16.2Hz,1H,piperazineCH),3.53(d,J＝16.2Hz,1H,piperazineCH),3.28–3.18(m,2H,piperazine-CH2),3.18–3.12(m,2H,piperazine-CH2),3.10(s,3H,NCH3),2.84(dd,J＝13.4,4.8Hz,1H,PhCH),2.62(dd,J＝13.4,9.5Hz,1H,PhCH).
13C NMR(100MHz,DMSO-d6)δ171.37(C＝O),167.32(C＝O),163.59(C＝O),159.00,139.16,137.90,135.89,133.91,130.25(2×C),130.05(2×C),129.28(2×C),129.12(2×C),128.59(2×C),126.88,115.13(2×C),55.88,51.81,48.87,48.43,46.94,43.09,37.77,37.69.
ESI-HRMS:m/z 599.1725(M+1),1219.3204(2M+23).C29H31ClN4O6S[598.1653].
reaction of the corresponding substituted benzenesulfonyl chloride with 4-bromobenzenesulfonyl chloride (145mg,0.57mmol,1.5eq.) with intermediate 6(160mg,0.38mmol, 1eq.), triethylamine (104 μ L,0.75mmol,2eq.) gave 75mg of (S) -2- (2- (4- ((4-bromophenyl) sulfonyl) -2-oxopiperazin-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (7f) as a white solid in 31% yield, m.p.: 204 ℃ and 205 ℃.
Spectral data:
1H NMR(400MHz,DMSO-d6)δ8.42(d,J＝8.0Hz,1H,NH),7.94(d,J＝8.5Hz,2H,Ph-H),7.80(d,J＝8.5Hz,2H,Ph-H),7.30–7.20(m,3H,Ph-H),7.17(d,J＝8.0Hz,2H,Ph-H),7.03(d,J＝8.8Hz,2H,Ph-H),6.94–6.83(m,2H,Ph-H),4.50(td,J＝8.7,5.2Hz,1H,CH),3.94(d,J＝16.5Hz,1H,piperazine-CH),3.89(d,J＝16.7Hz,1H,piperazine-CH),3.84(s,3H,OCH3),3.65(d,J＝16.2Hz,1H,piperazineCH),3.59(d,J＝16.2Hz,1H,piperazineCH),3.33–3.24(m,2H,piperazine-CH2),3.24–3.19(m,2H,piperazine-CH2),3.15(s,3H,NCH3),2.90(dd,J＝13.5,4.8Hz,1H,PhCH),2.68(dd,J＝13.4,9.4Hz,1H,PhCH).
13C NMR(100MHz,DMSO-d6)δ171.37(C＝O),167.32(C＝O),163.59(C＝O),159.00,137.90,135.89,134.30,133.19(2×C),130.10(2×C),129.28(2×C),129.13(2×C),128.59(2×C),128.25,126.88,115.13(2×C),55.89,51.82,48.86,48.43,46.95,43.08,37.77,37.68.
ESI-HRMS:m/z 643.1224(M+1).C29H31BrN4O6S[642.1148].
reaction of the correspondingly substituted benzenesulfonyl chloride with 4-methoxybenzenesulfonyl chloride (117mg,0.57mmol,1.5eq.) with intermediate 6(160mg,0.38mmol, 1eq.), triethylamine (104 μ L,0.75mmol,2eq.) produced 89mg of (S) -2- (2- (4- ((4-methoxyphenyl) sulfonyl) -2-oxopiperazin-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropanamide (7g) as a white solid in 40% yield, m.p.: 199 ℃ and 200 ℃.
Spectral data:
1H NMR(400MHz,DMSO-d6)δ8.38(d,J＝8.0Hz,1H,NH),7.75(d,J＝8.8Hz,2H,Ph-H),7.25–7.14(m,5H,Ph-H),7.11(d,J＝7.8Hz,2H,Ph-H),6.98(d,J＝8.8Hz,2H,Ph-H),6.88–6.78(m,2H,Ph-H),4.44(td,J＝8.7,5.1Hz,1H,CH),3.95–3.83(m,5H,PhOCH3+piperazine-CH2),3.79(s,3H,OCH3),3.51(d,J＝16.2Hz,1H,piperazine-CH),3.45(d,J＝16.2Hz,1H,piperazine-CH),3.22–3.15(m,2H,piperazine-CH2),3.15–3.12(m,2H,piperazine-CH2),3.10(s,3H,NCH3),2.84(dd,J＝13.5,4.8Hz,1H,PhCH),2.63(dd,J＝13.4,9.4Hz,1H,PhCH).
13C NMR(100MHz,DMSO-d6)δ171.36(C＝O),167.33(C＝O),163.71,163.62(C＝O),159.00,137.90,135.89,130.47(2×C),129.28(2×C),129.12(2×C),128.59(2×C),126.87,126.09,115.26(2×C),115.13(2×C),56.25,55.88,51.81,49.08,48.39,46.93,43.23,37.77,37.70.
ESI-HRMS:m/z 595.2226(M+1),1211.4210(2M+23).C30H34N4O7S[594.2148].
the corresponding substituted benzenesulfonyl chloride was reacted with 4-methylbenzenesulfonyl chloride (101mg,0.53mmol,1.5eq.) with intermediate 6(150mg,0.35mmol, 1eq.), triethylamine (98 μ L,0.71mmol,2eq.) to give 132mg of (S) -N- (4-methoxyphenyl) -N-methyl-2- (2- (2-oxo-4-tolylpiperazin-1-yl) acetylamino) -3-phenylpropanamide (7h) as a white solid in 65% yield, m.p.: 206- & lt207 & gt.
Spectral data:
1H NMR(400MHz,DMSO-d6)δ8.35(d,J＝8.0Hz,1H,NH),7.70(d,J＝8.1Hz,2H,Ph-H),7.48(d,J＝8.1Hz,2H,Ph-H),7.21–7.14(m,3H,Ph-H),7.10(d,J＝7.9Hz,2H,Ph-H),6.97(d,J＝8.8Hz,2H,Ph-H),6.87–6.76(m,2H,Ph-H),4.44(td,J＝8.7,5.1Hz,1H,CH),3.87(d,J＝16.5Hz,1H,piperazine-CH),3.82(d,J＝17.7Hz,1H,piperazine-CH),3.78(s,3H,OCH3),3.52(d,J＝16.2Hz,1H,piperazineCH),3.46(d,J＝16.2Hz,1H,piperazineCH),3.21–3.12(m,4H,piperazine-CH2×2),3.09(s,3H,NCH3),2.83(dd,J＝13.5,4.9Hz,1H,PhCH),2.62(dd,J＝13.4,9.4Hz,1H,PhCH),2.42(s,3H,PhCH3).
13C NMR(100MHz,DMSO-d6)δ171.35(C＝O),167.32(C＝O),163.65(C＝O),158.99,144.72,137.90,135.89,131.80,130.55(2×C),129.28(2×C),129.12(2×C),128.58(2×C),128.20(2×C),126.87,115.13(2×C),55.88,51.80,49.01,48.41,46.94,43.21,37.76,37.70,21.53.
ESI-HRMS:m/z 579.2275(M+1),1179.4327(2M+23).C30H34N4O6S[578.2199].
reaction of the corresponding substituted benzenesulfonyl chloride with 4-nitrobenzenesulfonyl chloride (212mg,0.95mmol,1.5eq.) with intermediate 6(270mg,0.64mmol, 1eq.), triethylamine (176 μ L,1.27mmol,2eq.) gave 264mg of (S) -N- (4-methoxyphenyl) -N-methyl-2- (2- (4- ((4-nitrophenyl) sulfonyl) -2-oxopiperazin-1-yl) acetamido) -3-phenylpropanamide (7i) as a white solid in 68% yield, melting point: 212 ℃ and 213 ℃.
Spectral data:
1H NMR(400MHz,DMSO-d6)δ8.45(d,J＝8.7Hz,2H,Ph-H),8.38(d,J＝7.9Hz,1H,NH),8.10(d,J＝8.7Hz,2H,Ph-H),7.23–7.16(m,3H,Ph-H),7.10(d,J＝7.9Hz,2H,Ph-H),6.97(d,J＝8.7Hz,2H,Ph-H),6.88–6.79(m,2H,Ph-H),4.44(td,J＝8.6,5.3Hz,1H,CH),3.90(d,J＝16.4Hz,1H,piperazine-CH),3.83(d,J＝16.0Hz,1H,piperazine-CH),3.79(s,3H,OCH3),3.68(d,J＝16.5Hz,1H,piperazineCH),3.63(d,J＝16.4Hz,1H,piperazineCH),3.34–3.26(m,2H,piperazine-CH2),3.18(t,J＝5.0Hz,2H,piperazine-CH2),3.10(s,3H,NCH3),2.84(dd,J＝13.5,4.8Hz,1H,PhCH),2.62(dd,J＝13.4,9.4Hz,1H,PhCH).
13C NMR(100MHz,DMSO-d6)δ171.34(C＝O),167.29(C＝O),163.44(C＝O),158.99,150.75,140.99,137.89,135.88,129.71(2×C),129.28(2×C),129.10(2×C),128.59(2×C),126.88,125.32(2×C),115.12(2×C),55.88,51.81,48.69,48.40,46.92,43.06,37.76,37.72
ESI-HRMS:m/z 610.1961(M+1),632.1739(M+23).C29H31N5O8S[609.1893].
the corresponding substituted benzenesulfonyl chloride was reacted with 3-nitrobenzenesulfonyl chloride (212mg,0.95mmol,1.5eq.) with intermediate 6(270mg,0.64mmol, 1eq.), triethylamine (176 μ L,1.27mmol,2eq.) to give 277mg of (S) -N- (4-methoxyphenyl) -N-methyl-2- (2- (4- ((3-nitrophenyl) sulfonyl) -2-oxopiperazin-1-yl) acetamido) -3-phenylpropanamide (7j) as a white solid in 71% yield and melting point: 159 ℃ to 160 ℃.
Spectral data:
1H NMR(400MHz,DMSO-d6)δ8.62–8.53(m,1H,Ph-H),8.50–8.42(m,1H,Ph-H),8.39(d,J＝7.9Hz,1H,NH),8.26(d,J＝7.9Hz,1H,Ph-H),7.97(t,J＝8.0Hz,1H,Ph-H),7.26–7.14(m,3H,Ph-H),7.11(d,J＝7.9Hz,2H,Ph-H),6.97(d,J＝8.8Hz,2H,Ph-H),6.87–6.76(m,2H,Ph-H),4.43(td,J＝8.7,5.3Hz,1H,CH),3.90(d,J＝16.4Hz,1H,piperazine-CH),3.83(d,J＝16.7Hz,1H,piperazine-CH),3.79(s,3H,OCH3),3.70(d,J＝16.3Hz,1H,piperazineCH),3.64(d,J＝16.4Hz,1H,piperazineCH),3.34–3.26(m,2H,piperazine-CH2),3.19(t,J＝5.1Hz,2H,piperazine-CH2),3.10(s,3H,NCH3),2.84(dd,J＝13.5,4.9Hz,1H,PhCH),2.62(dd,J＝13.4,9.4Hz,1H,PhCH).
13C NMR(100MHz,DMSO-d6)δ171.35(C＝O),167.30(C＝O),163.48(C＝O),158.99,148.74,137.89,136.83,135.89,134.01,132.15,129.28(2×C),129.11(2×C),128.63,128.59(2×C),126.88,122.86,115.12(2×C),55.89,51.82,48.74,48.36,46.92,43.11,37.76,37.71.
ESI-HRMS:m/z 610.1970(M+1),1241.3681(2M+23).C29H31N5O8S[609.1893].
the corresponding substituted benzenesulfonyl chloride was reacted with 2-nitrobenzenesulfonyl chloride (188mg,0.85mmol,1.5eq.) with intermediate 6(240mg,0.57mmol, 1eq.), triethylamine (157 μ L,1.13mmol,2eq.) to give (S) -N- (4-methoxyphenyl) -N-methyl-2- (2- (4- ((2-nitrophenyl) sulfonyl) -2-oxopiperazin-1-yl) acetamido) -3-phenylpropanamide (7k)205mg as a white solid in 59% yield, melting point: 160 ℃ and 161 ℃.
Spectral data:
1H NMR(400MHz,DMSO-d6)δ8.40(d,J＝8.0Hz,1H,NH),8.09(d,J＝7.6Hz,1H,Ph-H),8.04(d,J＝7.7Hz,1H,Ph-H),7.95(t,J＝7.3Hz,1H,Ph-H),7.88(t,J＝7.4Hz,1H,Ph-H),7.23–7.15(m,3H,Ph-H),7.12(d,J＝8.1Hz,2H,Ph-H),6.98(d,J＝8.8Hz,2H,Ph-H),6.84(d,J＝7.1Hz,2H,Ph-H),4.46(td,J＝8.7,5.2Hz,1H,CH),3.94(d,J＝16.5Hz,1H,piperazine-CH),3.88(d,J＝16.6Hz,1H,piperazine-CH),3.85(s,2H,piperazineCH2),3.79(s,3H,OCH3),3.49(t,J＝5.2Hz,2H,piperazine-CH2),3.20(t,J＝5.1Hz,2H,piperazine-CH2),3.11(s,3H,NCH3),2.86(dd,J＝13.5,4.8Hz,1H,PhCH),2.64(dd,J＝13.4,9.4Hz,1H,PhCH).
13C NMR(100MHz,DMSO-d6)δ171.36(C＝O),167.34(C＝O),163.60(C＝O),159.00,148.34,137.91,135.90,135.65,133.08,131.07,129.29(2×C),129.21,129.13,128.60(2×C),126.89,124.88(2×C),115.14(2×C),55.89,51.83,48.54,48.47,47.26,43.00,37.77,37.73.
ESI-HRMS:m/z 610.1965(M+1),1241.3695(2M+23).C29H31N5O8S[609.1893].
example 7: preparation of target Compound (7l-n)
Dissolve 7i (150mg,0.246mmol) in methanol: dichloromethane (8mL:8mL), then 10% Pd.C (18mg) is added, hydrogen is replaced for three times, and the mixture is stirred for two hours at room temperature under the protection of a hydrogen balloon; after the reaction, adding diatomite for filtration, evaporating the filtrate to dryness to obtain a crude target compound, and purifying the crude target compound by using a silica gel preparation plate to obtain 87mg of a pure target compound (S) -2- (2- (4- ((4-aminophenyl) sulfonyl) -2-oxopiperazin-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropionamide (7l) as a white solid with the yield of 61% and the melting point: 128-129 ℃.
Spectral data:
1H NMR(400MHz,DMSO-d6)δ8.37(d,J＝7.9Hz,1H,NH),7.42(d,J＝8.6Hz,2H,Ph-H),7.30–7.15(m,3H,Ph-H),7.12(d,J＝7.9Hz,2H,Ph-H),6.98(d,J＝8.8Hz,2H,Ph-H),6.88–6.79(m,2H,Ph-H),6.68(d,J＝8.7Hz,2H,Ph-H),6.20(s,2H,NH2),4.44(td,J＝8.8,5.2Hz,1H,CH),3.86(s,2H,piperazine-CH2),3.79(s,3H,OCH3),3.46–3.36(m,2H,piperazineCH2),3.23–3.12(m,2H,piperazine-CH2),3.10(s,3H,NCH3),3.07–2.95(m,2H,piperazine-CH2),2.84(dd,J＝13.5,4.8Hz,1H,PhCH),2.63(dd,J＝13.4,9.5Hz,1H,PhCH).
13C NMR(100MHz,DMSO-d6)δ171.38(C＝O),167.38(C＝O),163.98(C＝O),158.99,154.17,137.91,135.90,130.31(2×C),129.29(2×C),129.14(2×C),128.58(2×C),126.88,118.49,115.14(2×C),113.30(2×C),55.88,51.83,49.30,48.38,46.94,43.32,37.77,37.66.
ESI-HRMS:m/z 580.2228(M+1),1181.4192(2M+23).C29H33N5O6S[579.2152].
dissolving 7j (150mg,0.246mmol) in methanol-dichloromethane (5mL:5mL), adding 10% Pd.C (20mg), replacing with hydrogen for three times, and stirring at room temperature for two hours under the protection of a hydrogen balloon; after the reaction, adding diatomite for filtration, evaporating the filtrate to dryness to obtain a crude target compound, and purifying by a silica gel preparation plate to obtain 101mg of a pure target compound (S) -2- (2- (4- ((3-aminophenyl) sulfonyl) -2-oxopiperazin-1-yl) acetylamino) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropionamide (7m), wherein the yield is 71%, the melting point is: 106-107 ℃.
Spectral data:
1H NMR(400MHz,DMSO-d6)δ8.39(d,J＝8.0Hz,1H,NH),7.28(t,J＝7.9Hz,1H,Ph-H),7.24–7.15(m,3H,Ph-H),7.12(d,J＝7.7Hz,2H,Ph-H),7.02–6.93(m,3H,Ph-H),6.93–6.79(m,4H,Ph-H),5.71(s,2H,NH2),4.44(td,J＝8.8,5.2Hz,1H,CH),3.86(s,2H,piperazine-CH2),3.79(s,3H,OCH3),3.50(d,J＝16.2Hz,1H,piperazineCH),3.45(d,J＝16.3Hz,1H,piperazineCH),3.23–3.11(m,4H,piperazine-CH2×2),3.10(s,3H,NCH3),2.84(dd,J＝13.5,4.7Hz,1H,PhCH),2.63(dd,J＝13.4,9.5Hz,1H,PhCH).
13C NMR(100MHz,DMSO-d6)δ171.37(C＝O),167.35(C＝O),163.72(C＝O),159.00,150.26,137.91,135.90,134.84,130.43,129.28(2×C),129.14(2×C),128.59(2×C),126.88,118.83,115.14(2×C),114.54,112.15,55.88,51.83,49.15,48.44,47.00,43.31,37.77,37.66.
ESI-HRMS:m/z 580.2220(M+1),1181.4181(2M+23).C29H33N5O6S[579.2152].
dissolve 7k (150mg,0.246mmol) in methanol: dichloromethane (5mL:5mL), then 10% Pd.C (20mg) is added, hydrogen is replaced for three times, and the mixture is stirred for two hours at room temperature under the protection of a hydrogen balloon; after the reaction is finished, adding diatomite for filtration, evaporating the filtrate to dryness to obtain a crude target compound, and purifying by a silica gel preparation plate to obtain a pure target compound (S) -2- (2- (4- ((2-aminophenyl) sulfonyl) -2-oxopiperazin-1-yl) acetamido) -N- (4-methoxyphenyl) -N-methyl-3-phenylpropionamide (7N)114mg, a white solid, the yield of 80%, and the melting point: 95-96 ℃.
Spectral data:
1H NMR(400MHz,DMSO-d6)δ8.37(d,J＝8.0Hz,1H,NH),7.44(d,J＝7.9Hz,1H,Ph-H),7.36(t,J＝7.6Hz,1H,Ph-H),7.22–7.15(m,3H,Ph-H),7.12(d,J＝7.7Hz,2H,Ph-H),6.98(d,J＝8.8Hz,2H,Ph-H),6.90(d,J＝8.3Hz,1H,Ph-H),6.87–6.79(m,2H,Ph-H),6.68(t,J＝7.5Hz,1H,Ph-H),6.14(s,2H,NH2),4.45(td,J＝8.7,5.2Hz,1H,CH),3.86(s,2H,piperazine-CH2),3.79(s,3H,OCH3),3.61(d,J＝16.3Hz,1H,piperazineCH),3.56(d,J＝16.3Hz,1H,piperazineCH),3.29–3.20(m,2H,piperazine-CH2),3.20–3.13(m,2H,piperazine-CH2),3.10(s,3H,NCH3),2.84(dd,J＝13.5,4.8Hz,1H,PhCH),2.64(dd,J＝13.4,9.5Hz,1H,PhCH).
13C NMR(100MHz,DMSO-d6)δ171.37(C＝O),167.36(C＝O),163.85(C＝O),159.00,148.26,137.91,135.90,135.17,130.39,129.28(2×C),129.13(2×C),128.58(2×C),126.88,118.02,115.92,115.14(2×C),114.39,55.89,51.83,48.91,48.42,46.94,43.14,37.77,37.68.
ESI-HRMS:m/z 580.2225(M+1),1181.4212(2M+23).C29H33N5O6S[579.2152].
example 8 in vitro anti-HIV-1 Activity test (TZM-bl cells) of Compounds of interest
The principle is as follows: luciferase reporter Gene experiments (nef Gene deleted HIV-1NL4-3)
The test method comprises the following steps:
anti-HIV-1 infection assay in TZM-bl cells
The inhibitory activity of a compound against HIV-1 infection was determined as the degree of decrease in the expression level of luciferase gene following a single round of viral infection of TZM-bl cells. Briefly, 800TCID was used in the presence of different concentrations of compounds (7a-7n and PF-74)50The virus of (NL4-3) infects TZM-bl cells. After 1 day of infection, the culture broth was removed and 100 μ LBright Glo reagent (Promega, San Luis Obispo, CA) was added to each well before its fluorescence activity was measured using a Victor 2 luminometer. Effective concentration of compound (EC) for inhibiting HIV-1 strain50) Defined as the concentration that results in a 50% decrease in luciferase activity (relative light units) compared to the virus control wells.
Cytotoxicity assays
Cytotoxicity of the synthesized compounds was determined using the CytoTox-Glo fluorescent cytotoxicity kit (purchased from Promega). TZM-bl cells were cultured for 1 day in the presence of different concentrations of compounds (7a-7n and PF-74), as determined in parallel with the anti-HIV-1 activity assay. The cytotoxicity (CC) of the tested target compound is then determined according to the procedure required by the kit50) I.e. targetingThe concentration of compound required to reduce cell survival by 50%.
TABLE 1 phenylalanine derivatives containing in part 4- (phenylsulfonyl) piperazin-2-one anti-HIV-1 Activity, toxicity and selection index (TZM-bl cells)
aEC50: concentration of compound that protects 50% of HIV-1 infected cells from cytopathic effects;
bCC50: (ii) concentration of compound that causes lesions in 50% of cells not infected with HIV-1;
cand (3) SI: coefficient of selectivity, CC50/EC50The ratio of (A) to (B);
PF-74: a class of HIV-1 capsid inhibitors has been reported as positive controls.
And (4) experimental conclusion analysis: as shown in Table 1, the newly synthesized phenylalanine derivatives containing 4- (phenylsulfonyl) piperazin-2-one of the present invention exhibited significant anti-HIV-1 activity. For example, the anti-HIV-1 activity of the target compounds 7a, 7c, 7d, 7f, 7h, 7i, 7l, 7M, 7n was in the range of 0.09-0.54. mu.M, which was superior to that of the positive control PF-74 (EC)50＝0.52±0.18μM,CC50>47.00,SI>90.91) or equivalent, wherein the anti-HIV-1 activity (EC) of 7l of the compound of interest50＝0.09±0.03μM,CC50>34.50,SI>383.36) has great significance in further research.
Claims (7)
1. A phenylalanine derivative containing 4- (phenylsulfonyl) piperazin-2-one, or a pharmaceutically acceptable salt, ester, or prodrug thereof, having the structure shown in formula I:
wherein,
r is: c1-C6Alkyl, OC1-C6Alkyl radical, C2-C6Alkenyl radical, C3-C6Cycloalkyl, OC3-C6Cycloalkyl, substituted benzene ring, substituted benzyl, substituted naphthalene ring, various substituted six-membered heterocyclic rings or various substituted five-membered heterocyclic rings, H, OH, halogen, nitro, amino, cyano, trifluoromethyl or trifluoromethoxy.
2. The phenylalanine derivative containing 4- (phenylsulfonyl) piperazin-2-one according to claim 1, wherein R is: H. 4-F, 3-F, 2-F, 4-Cl, 3-Cl, 2-Cl, 4-Br, 3-Br, 2-Br, 4-methoxy, 3-methoxy, 2-methoxy, 4-methyl, 3-methyl, 2-methyl, 4-nitro, 3-nitro, 2-nitro, 4-amino, 3-amino and 2-amino.
3. The phenylalanine derivative containing 4- (phenylsulfonyl) piperazin-2-one according to claim 1 or 2, characterized in that the compound is one of the following:
4. the method for preparing a phenylalanine derivative containing 4- (phenylsulfonyl) piperazin-2-one according to claim 1, comprising the steps of: generating an intermediate 2 with Boc-L-phenylalanine 1 as an initial raw material and dichloromethane as a reaction solvent through an amide condensation reaction and N-methyl-4-aminoanisole; then the intermediate 2 is dissolved in a proper amount of dichloromethane, and Boc groups are removed under the action of trifluoroacetic acid to obtain an intermediate 3; then, carrying out amide condensation reaction on the intermediate 3 and bromoacetic acid to obtain an intermediate 4; the intermediate 4 and 3-oxo-1-piperazine carboxylic acid tert-butyl ester take nucleophilic substitution reaction by taking dichloromethane as a solvent to obtain an intermediate 5; then, dissolving the intermediate 5 in a proper amount of dichloromethane solution, and removing Boc groups under the action of trifluoroacetic acid to obtain an intermediate 6; finally, the intermediate 6 and the corresponding substituted benzene sulfonyl chloride are subjected to sulfonylation reaction to obtain a target compound (7 a-k); further hydrogenating and reducing the compound (7i-k) to obtain a target compound (7 l-n);
the synthetic route is as follows:
reagents and conditions: (i) n-methyl-4-aminoanisole, 1H-benzotriazole-1-yloxytripyrrolidinyl hexafluorophosphate, N, N-diisopropylethylamine and dichloromethane are added, and the temperature is changed to room temperature at 0 ℃; (ii) trifluoroacetic acid, dichloromethane, room temperature; (iii) bromoacetic acid, O- (7-azabenzotriazol-1-yl) -N, N, N ', N' -tetramethyluronium hexafluorophosphate, N, N-diisopropylethylamine and dichloromethane, and the temperature is changed to room temperature at 0 ℃; (iv) 3-oxo-1-piperazine carboxylic acid tert-butyl ester, potassium carbonate and N, N-dimethylformamide, and the temperature is changed to 40 ℃ at room temperature; (v) trifluoroacetic acid, dichloromethane, room temperature; (vi) correspondingly substituted benzene sulfonyl chloride, triethylamine and dichloromethane are cooled to room temperature at 0 ℃; (vii) h210% Pd · C, dichloromethane/methanol, room temperature;
wherein R is as defined in formula I in claim 1;
the substituted benzene sulfonyl chloride is benzene sulfonyl chloride, 4-fluorobenzene sulfonyl chloride, 3-fluorobenzene sulfonyl chloride, 2-fluorobenzene sulfonyl chloride, 4-chlorobenzene sulfonyl chloride, 4-bromobenzene sulfonyl chloride, 4-methoxybenzene sulfonyl chloride, 4-methylbenzene sulfonyl chloride, 4-nitrobenzene sulfonyl chloride, 3-nitrobenzene sulfonyl chloride and 2-nitrobenzene sulfonyl chloride.
5. The method for preparing a phenylalanine derivative containing 4- (phenylsulfonyl) piperazin-2-one according to claim 4, comprising the steps of:
(1) adding Boc-L-phenylalanine 1 and 1H-benzotriazole-1-yloxytripyrrolidinyl hexafluorophosphate into dichloromethane, and stirring for 30min under an ice bath condition; adding N, N-diisopropylethylamine and N-methyl-4-aminoanisole into the reaction solution, removing the ice bath, transferring to room temperature, and monitoring by TLC; after the reaction is finished, evaporating the solvent under reduced pressure, then adding a saturated sodium bicarbonate solution into the residue in the bottle, extracting with dichloromethane, separating an organic phase, adding a 1N HCl solution for washing, separating the organic phase, adding a saturated sodium chloride solution for washing, drying the organic phase with anhydrous sodium sulfate, filtering, concentrating the filtrate under reduced pressure, and separating and purifying the obtained crude product by silica gel column chromatography to obtain an intermediate 2;
(2) adding the intermediate 2 obtained in the previous step into dichloromethane, slowly dropwise adding excessive trifluoroacetic acid into the solution under the condition of ice bath and stirring, then removing the ice bath, transferring to room temperature, and monitoring by TLC; after the reaction is finished, evaporating the solvent under reduced pressure, adding a saturated sodium bicarbonate solution to adjust the pH of the reaction solution to 7, and then adding a dichloromethane solution for extraction; separating and taking an organic phase, washing the organic phase for 3 times by using a saturated sodium chloride solution, drying the organic phase by using anhydrous sodium sulfate, filtering, and evaporating the solvent to dryness under reduced pressure to obtain an intermediate 3;
(3) adding bromoacetic acid and O- (7-azabenzotriazole-1-yl) -N, N, N ', N' -tetramethylurea hexafluorophosphate into dichloromethane, and stirring for 1h under an ice bath condition; then adding the intermediate 3 and N, N-diisopropylethylamine into the solution, removing the ice bath, and stirring at room temperature for 6 h; after the reaction is finished, filtering, decompressing and evaporating the solvent, and separating by silica gel column chromatography to obtain an intermediate 4;
(4) adding the intermediate 4, the tert-butyl 3-oxo-1-piperazinecarboxylate and potassium carbonate into N, N-dimethylformamide, and stirring for 12 hours from room temperature to 40 ℃; after the reaction is finished, adding a proper amount of saturated sodium chloride solution into the reaction solution, extracting with ethyl acetate, drying an organic phase with anhydrous sodium sulfate, filtering, evaporating the solvent under reduced pressure, and separating by silica gel column chromatography to obtain an intermediate 5;
(5) adding the intermediate 5 into dichloromethane, slowly adding trifluoroacetic acid into the dichloromethane under the condition of ice bath and stirring, then removing the ice bath, transferring the mixture to room temperature, and monitoring by TLC; after the reaction is finished, evaporating the solvent under reduced pressure, adding a saturated sodium bicarbonate solution to adjust the pH of the reaction solution to 7, and then adding a dichloromethane solution for extraction; separating and taking an organic phase, washing the organic phase for 3 times by using a saturated sodium chloride solution, drying the organic phase by using anhydrous sodium sulfate, filtering, and evaporating the solvent to dryness under reduced pressure to obtain an intermediate 6;
(6) adding the intermediate 6 and triethylamine into dichloromethane, slowly adding the corresponding substituted benzenesulfonyl chloride into the dichloromethane under the condition of ice bath and stirring, removing the ice bath, transferring to room temperature, and monitoring by TLC; after the reaction is finished, adding saturated sodium chloride solution, extracting by dichloromethane, separating and taking an organic phase, drying by using anhydrous sodium sulfate, filtering, evaporating the solvent by decompression, separating by silica gel column chromatography to obtain a crude product of the target compound, and recrystallizing by ethyl acetate to obtain a pure product (7a-k) of the target compound;
(7) dissolving a target compound (7i-k) in methanol and dichloromethane, adding 10% Pd & C, replacing with hydrogen for three times, and stirring at room temperature for two hours under the protection of a hydrogen balloon; after the reaction is finished, adding diatomite for filtration, evaporating the filtrate to dryness to obtain a crude product of the target compound, and purifying by a silica gel preparation plate to obtain a pure product (7l-7n) of the target compound.
6. Use of phenylalanine derivatives containing 4- (phenylsulfonyl) piperazin-2-one according to any of claims 1-3 for the preparation of a medicament for the treatment and prevention of aids.
7. An anti-HIV pharmaceutical composition comprising a phenylalanine derivative containing 4- (phenylsulfonyl) piperazin-2-one or a pharmaceutically acceptable salt thereof according to any one of claims 1-3 and one or more pharmaceutically acceptable carriers or excipients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910206946.6A CN109824756B (en) | 2019-03-19 | 2019-03-19 | Phenylalanine derivative containing 4- (benzenesulfonyl) piperazine-2-ketone and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910206946.6A CN109824756B (en) | 2019-03-19 | 2019-03-19 | Phenylalanine derivative containing 4- (benzenesulfonyl) piperazine-2-ketone and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109824756A true CN109824756A (en) | 2019-05-31 |
| CN109824756B CN109824756B (en) | 2022-03-22 |
Family
ID=66870390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910206946.6A Active CN109824756B (en) | 2019-03-19 | 2019-03-19 | Phenylalanine derivative containing 4- (benzenesulfonyl) piperazine-2-ketone and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109824756B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111454233A (en) * | 2020-05-08 | 2020-07-28 | 河南大学 | 4- (2- (pyrrolidine/piperidine-1-yl) benzyl) -piperazinylurea TRPV1 antagonist and preparation and application thereof |
| CN113105395A (en) * | 2021-04-22 | 2021-07-13 | 山东大学 | 4-phenylsulfonyl-1-trihydroxy benzoyl piperazine-2-carboxamide derivative and preparation method and application thereof |
| CN113461639A (en) * | 2021-07-08 | 2021-10-01 | 贵州大学 | Piperazine-containing ferulic acid derivative, and preparation method and application thereof |
| CN114456228A (en) * | 2022-02-21 | 2022-05-10 | 山东大学 | Substituted glycine-3, 5-difluorophenylalanine peptide derivative and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6465433B1 (en) * | 1994-10-28 | 2002-10-15 | Millennium Pharmaceuticals, Inc. | Boronic ester and acid compounds, synthesis and uses |
| CN1530372A (en) * | 1995-03-10 | 2004-09-22 | G.D.ɪ����˾ | Inhibitor of hecterocyclic oxoaminoethylol aminosulfonic amine reverse transcripted virus protenase |
| WO2013006792A1 (en) * | 2011-07-07 | 2013-01-10 | Pharmaresources (Shanghai) Co., Ltd. | Antiviral compounds |
| CN104387299A (en) * | 2014-10-23 | 2015-03-04 | 凯莱英医药集团（天津）股份有限公司 | Method for preparing 4-amino-N-[(2R,3S)-3-amino-2-hydroxy-4-benzene butyl]-N-isobutyl benzsulfamide |
| WO2015061518A1 (en) * | 2013-10-24 | 2015-04-30 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
-
2019
- 2019-03-19 CN CN201910206946.6A patent/CN109824756B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6465433B1 (en) * | 1994-10-28 | 2002-10-15 | Millennium Pharmaceuticals, Inc. | Boronic ester and acid compounds, synthesis and uses |
| CN1530372A (en) * | 1995-03-10 | 2004-09-22 | G.D.ɪ����˾ | Inhibitor of hecterocyclic oxoaminoethylol aminosulfonic amine reverse transcripted virus protenase |
| WO2013006792A1 (en) * | 2011-07-07 | 2013-01-10 | Pharmaresources (Shanghai) Co., Ltd. | Antiviral compounds |
| WO2015061518A1 (en) * | 2013-10-24 | 2015-04-30 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| CN104387299A (en) * | 2014-10-23 | 2015-03-04 | 凯莱英医药集团（天津）股份有限公司 | Method for preparing 4-amino-N-[(2R,3S)-3-amino-2-hydroxy-4-benzene butyl]-N-isobutyl benzsulfamide |
Non-Patent Citations (2)
| Title |
|---|
| SUN LIN ET AL.: "Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
| 孙林: "新型HIV-1衣壳蛋白抑制剂和RNase H抑制剂的设计、合成与生物活性评价", 《中国博士学位论文全文数据库(电子期刊) 医药卫生科技辑》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111454233A (en) * | 2020-05-08 | 2020-07-28 | 河南大学 | 4- (2- (pyrrolidine/piperidine-1-yl) benzyl) -piperazinylurea TRPV1 antagonist and preparation and application thereof |
| CN111454233B (en) * | 2020-05-08 | 2023-01-24 | 河南大学 | 4- (2- (pyrrolidine/piperidine-1-yl) benzyl) -piperazinylurea TRPV1 antagonist and preparation and application thereof |
| CN113105395A (en) * | 2021-04-22 | 2021-07-13 | 山东大学 | 4-phenylsulfonyl-1-trihydroxy benzoyl piperazine-2-carboxamide derivative and preparation method and application thereof |
| CN113461639A (en) * | 2021-07-08 | 2021-10-01 | 贵州大学 | Piperazine-containing ferulic acid derivative, and preparation method and application thereof |
| CN113461639B (en) * | 2021-07-08 | 2022-11-01 | 贵州大学 | Piperazine-containing ferulic acid derivative, and preparation method and application thereof |
| CN114456228A (en) * | 2022-02-21 | 2022-05-10 | 山东大学 | Substituted glycine-3, 5-difluorophenylalanine peptide derivative and preparation method and application thereof |
| CN114456228B (en) * | 2022-02-21 | 2023-09-12 | 山东大学 | Substituted glycine-3, 5-difluorophenylalanine peptide derivative and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109824756B (en) | 2022-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109824756B (en) | Phenylalanine derivative containing 4- (benzenesulfonyl) piperazine-2-ketone and preparation method and application thereof | |
| CN108033952B (en) | Phenylalanine derivative and the preparation method and application thereof containing triazole ring | |
| ES2333445T3 (en) | DERIVATIVES OF 2-PHENYLPROPIONIC ACID AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| US5728718A (en) | 2,5-diamino-3,4-disubstituted-1,6-diphenylhexane isosteres comprising benzamide, sulfonamide and anthranilamide subunits and methods of using same | |
| EP2632895B1 (en) | Hiv protease inhibitors | |
| RU2577861C2 (en) | N-hydroxy-benzamides for treating cancer | |
| KR20110053379A (en) | A group of amino substituted benzoyl derivatives and their preparation and their use | |
| ES2294103T3 (en) | HIV PROTEASA INHIBITORS BASED ON AMINO ACID DERIVATIVES. | |
| CN109897088B (en) | Phenylalanine derivative containing N- (2-oxoethyl) benzene sulfonamide and preparation method and application thereof | |
| JPH05507686A (en) | N-(2-biphenylyl)guanidine derivatives with therapeutic potential | |
| JP3101677B2 (en) | Diphenylpiperazine derivatives and cardiovascular drugs containing the same | |
| JP6987125B2 (en) | New 2,4,6-trisubstituted s-triazine compound and its production method and use | |
| WO2008087514A2 (en) | Hdac inhibitors | |
| CN109836477B (en) | Phenylalanine derivative containing benzothiadiazine-3-ketone 1, 1-dioxide and preparation method and application thereof | |
| US5763464A (en) | Retroviral agents containing anthranilamide, substituted benzamide and other subunits, and methods of using same | |
| WO2011080562A1 (en) | Novel aza-peptides containing 2,2-disubstituted cyclobutyl and/or substituted alkoxy benzyl derivatives as antivirals | |
| WO2007005774A9 (en) | Novel derivatives of amino acids for treatment of obesity and related disorders | |
| EP1751125A1 (en) | Ritonavir analogous compound useful as retroviral protease inhibitor, preparation of the ritonavir analogous compound and pharmaceutical composition for the ritonavir analogous compound. | |
| CN108558808A (en) | A kind of amide derivatives or its pharmaceutically acceptable salt and its preparation method and application | |
| CN109796418B (en) | Phenylalanine derivative containing 4-phenyl-1, 2, 3-triazole and preparation method and application thereof | |
| CN115160193A (en) | Naphthalene sulfonamide micromolecule compound and application thereof | |
| CN105801464B (en) | Pyrrole amides class compound and preparation method thereof and purposes | |
| CN109824583B (en) | Phenyl oxamide HIV-1 inhibitor and preparation method and application thereof | |
| JP6848055B2 (en) | Synthetic method for producing enantiomerically pure cis-imidazoline compounds for pharmaceutical use | |
| WO2023077977A1 (en) | Method for preparing colchicine derivative and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |